Zimmer Biomet Holdings, Inc. (BVMF:Z1BH34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 97.90B -7.3% |
| Revenue (ttm) | 44.08B +8.6% |
| Net Income | 4.18B -2.0% |
| EPS | 5.59 +0.2% |
| Shares Out | n/a |
| PE Ratio | 21.72 |
| Forward PE | 10.84 |
| Dividend | 0.80 (0.65%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | n/a |
| Open | 121.50 |
| Previous Close | 121.50 |
| Day's Range | 121.50 - 121.50 |
| 52-Week Range | 111.66 - 129.09 |
| Beta | 0.49 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well a... [Read more]
Financial Performance
In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.
Financial numbers in USD Financial StatementsNews
Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 2026
Featured symposium will reveal a new vision for intelligent systems that support surgeon judgment, reduce procedural burden and connect the episode of care WARSAW, Ind., Oct. 29, 2026 /PRNewswire/ -- ...
3 of the Best Smaller-Cap Stocks to Own
These stocks of smaller companies with wide economic moats are good long-term buys when you can get them on sale.
Zimmer Biomet’s recent weakness offers a buying opportunity, says Argus
Argus analyst David Toung keeps a Buy rating and $125 price target on Zimmer Biomet (ZBH) but believes that the stock’s recent weakness offers a buying opportunity. The company has…
Zimmer Biomet and THINK Surgical extend exclusive distribution agreement
Zimmer Biomet (ZBH) and THINK Surgical, a company in the field of orthopedic surgical robots, announced a multi-year extension of its Limited Exclusive Distribution and Supply Agreement following a su...
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Multi-Year Extension to Help Accelerate Adoption of Wireless, Handheld TMINI® System for Use with Zimmer Biomet's Persona® Knee System FREMONT, Calif. and WARSAW, Ind.
Zimmer Biomet initiated with an Equal Weight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Zimmer Biomet (ZBH) with an Equal Weight rating and $100 price target The firm rolled out coverage of the medical suppliers and devices…
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
WARSAW, Ind., Oct. 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its third quarter earnings conference call will be webc...
Citi opens ‘upside 90-day catalyst watch’ on Zimmer Biomet
Citi analyst Joanne Wuensch opened an “upside 90-day catalyst watch” on Zimmer Biomet (ZBH) while keeping a Neutral rating on the shares with a $99 price target Citi sees reasonable…
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and ...
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment o...
Zimmer Biomet price target raised to $100 from $83 at Canaccord
Canaccord analyst Caitlin Cronin raised the firm’s price target on Zimmer Biomet (ZBH) to $100 from $83 and keeps a Hold rating on the shares. The firm updated its model…
Zimmer Biomet price target raised to $106 from $92 at Truist
Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $106 from $92 and keeps a Hold rating on the shares. Zimmer Biomet delivered a Q2 organic revenue beat…
Zimmer Biomet price target raised to $106 from $92 at Truist
Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $106 from $92 and keeps a Hold rating on the shares. The firm notes the company delivered a Q2…
Zimmer Biomet price target raised to $104 from $92 at Baird
Baird raised the firm’s price target on Zimmer Biomet (ZBH) to $104 from $92 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results.
Zimmer Biomet price target raised to $98 from $88 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Zimmer Biomet (ZBH) to $98 from $88 and keeps a Hold rating on the shares.
Zimmer Biomet price target raised to $120 from $115 at UBS
UBS analyst Patrick Wood raised the firm’s price target on Zimmer Biomet (ZBH) to $120 from $115 and keeps a Buy rating on the shares.
Zimmer Biomet price target raised to $110 from $105 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Zimmer Biomet (ZBH) to $110 from $105 and keeps a Buy rating on the shares.
Zimmer Biomet price target raised to $93 from $91 at Bernstein
Bernstein raised the firm’s price target on Zimmer Biomet (ZBH) to $93 from $91 and keeps a Market Perform rating on the shares following quarterly results. It was a solid…
Zimmer Biomet price target raised to $96 from $95 at BMO Capital
BMO Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $96 from $95 and keeps a Market Perform rating on the shares.
Zimmer Biomet price target raised to $110 from $101 at RBC Capital
RBC Capital analyst Kendall Au raised the firm’s price target on Zimmer Biomet (ZBH) to $110 from $101 and keeps an Outperform rating on the shares.
Zimmer Biomet price target raised to $99 from $93 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Zimmer Biomet (ZBH) to $99 from $93 and keeps a Neutral rating on the shares.
Zimmer Biomet Holdings Earnings Call Transcript: Q2 2026
Q2 sales grew 4.8% reported and 4% organically, led by strong U.S. hip and technology growth. Guidance for full-year organic revenue and adjusted EPS was raised, with robust cash flow and continued investments in innovation, Salesforce transformation, and M&A.
Zimmer Biomet Holdings Earnings release: Q2 2026
Zimmer Biomet Holdings released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Zimmer Biomet Holdings Quarterly report: Q2 2026
Zimmer Biomet Holdings has published its Q2 2026 quarterly earnings report on August 5, 2026.
Zimmer Biomet Announces Second Quarter 2026 Financial Results
Second quarter net sales of $2.177 billion increased 4.8% on a reported basis, 4.7% on a constant currency1 basis and 4.0% on an organic constant currency1 basis Second quarter diluted earnings per sh...